US-based pharmaceutical company BioPharmX will present research to demonstrate the connection between molecular iodine and healthy aging of women's breasts.
Titled as 'Molecular Iodine: the Missing Key to Healthy Aging of the Female Breast', the research is the only poster presentation on female breast health at Vitafoods Europe Conference.
BioPharmX Regulatory and Clinical affairs executive vice-president AnnaMarie Daniels said: "Our review of literature shows that adequate daily supplementation with molecular iodine yields protection against the development of fibrocystic tissue in breasts.
"Studies have repeatedly shown that taking the right kind of molecular iodine supplements can significantly improve the quality of life for women."
The research reviews three studies and has been conducted on more than 2,200 women.
The results conclude that molecular iodine can help gain back normal breast tissue, as well as reduce the symptoms of fibrocystic breast condition (FBC), along with other issues such as breast swelling, tenderness and pain.
At least 70% of premenopausal women are affected by FBC, which occurs when recurrent hormonal exposure increases cell division.
This often results in the formation of fibrous tissue, cysts and chronic inflammation.
BioPharmX has developed a new formulation of molecular iodine that provides the optimal dose required to alleviate FBC symptoms.
The product Violet iodine is commercially available in the US and also a subject of a multicentre clinical trial in women afflicted with moderate to severe FBC.
Vitafoods Europe Conference is an international meeting that discusses on the ingredients and raw materials for the functional food and drink, nutraceutical and nutricosmetics industries.